Trial Profile
A Multicenter, Retrospective Study Investigating the Efficacy and Safety of Daratumumab after Allogeneic Transplantation for Heavily Treated Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2018
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.